Multidimensional assessment of patient-reported outcomes and TCM syndrome improvement in allergic rhinitis: A retrospective cohort study of acupuncture combined with Yu Ping Feng San

针灸联合玉屏风散治疗过敏性鼻炎的多维度疗效评价:患者自述结局及中医证候改善的回顾性队列研究

阅读:2

Abstract

Allergic rhinitis (AR) is a common chronic condition that significantly impairs quality of life. Traditional Chinese medicine (TCM) recognizes lung qi deficiency and cold-type syndrome as a prevalent subtype. This study aimed to provide real-world evidence on the efficacy and safety of acupuncture combined with Yu Ping Feng San in treating this TCM subtype. A retrospective cohort study was conducted involving 91 patients with lung qi deficiency and cold-type AR treated at the Central Hospital of Changsha between January 2024 and May 2025. Patients were divided into an observation group (acupuncture + Yu Ping Feng San, n = 45) and a control group (fluticasone propionate nasal spray, n = 46). Primary outcomes included total efficacy rate, total nasal symptom score (TNSS), rhinoconjunctivitis quality of life questionnaire (RQLQ) score, TCM syndrome score, and serum total IgE level, evaluated at baseline, after 4 weeks of treatment, and at 4 weeks posttreatment follow-up. Adverse events were also recorded. After 4 weeks, the observation group showed a significantly higher total efficacy rate (84.44%) compared to the control group (65.22%) (χ² = 4.452, P = .035). TNSS and RQLQ scores were significantly lower in the observation group (4.29 ± 1.38 and 43.92 ± 14.33) versus the control group (5.18 ± 1.43, P = .003; 52.73 ± 13.47, P = .003). At follow-up, TNSS and RQLQ scores slightly increased but remained significantly better in the observation group (P < .001). Posttreatment serum IgE levels were also significantly lower in the observation group (113.51 ± 28.57 IU/mL vs 134.82 ± 30.73 IU/mL, P = .001). Adverse event rates were comparable (13.3% vs 15.2%, P = .797), with no serious events reported. Acupuncture combined with Yu Ping Feng San demonstrates superior efficacy in relieving symptoms, improving quality of life, and reducing serum IgE levels in lung qi deficiency and cold-type AR compared to fluticasone propionate alone. The therapy is well tolerated and shows sustained benefits posttreatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。